Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 6Phase 1/2 4

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma 45Breast Neoplasms 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Non-Hodgkin 39Multiple Myeloma 35Leukemia 34Leukemia, Lymphocytic, Chronic, B-Cell 32Melanoma 31Recurrence 29Leukemia, Myeloid, Acute 28Lymphoma, Follicular 27Lymphoma, B-Cell 25Ovarian Neoplasms 23Lymphoma, Mantle-Cell 23Neoplasm Metastasis 21Hematologic Neoplasms 19Myelodysplastic Syndromes 18Hodgkin Disease 18Pancreatic Neoplasms 17Burkitt Lymphoma 16Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Colorectal Neoplasms 12Stomach Neoplasms 11Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Carcinoma, Hepatocellular 9

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Cyclophosphamide × Clear all
NCT07523529 2026-04-13

SELECT-2CAR

Beijing Biotech

Phase 1/2 Recruiting
72 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06640582 2024-11-05

BAH2472

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡